Business Wire

Synteract Adds to Leadership Team with Rare and Orphan Disease Experts Lisa Dilworth and Elisabeth Schrader

Jaa

Synteract, an innovative contract research organization (CRO) enabling biopharma companies to bring new medicines to market, has added two experienced members to enhance its Rare and Orphan Diseases Center of Development. Lisa Dilworth joins as vice president, rare and orphan diseases, and Elisabeth Schrader as executive director, program strategy, pediatrics and rare diseases.

Synteract has a long history of providing rare and orphan clinical trial expertise, across all phases of drug development, with more than 136 trials performed in the last five years across 50+ indications. It specializes in studies for diseases that affect a small portion of the population, where it applies its considerable operational acumen to studies that have never been done before.

“Studies for diseases that affect a small portion of the population have been a mainstay of Synteract’s for many years. With extensive and varied backgrounds in rare and orphan drug development, Lisa and Elisabeth are excellent additions to our development center,” said Steve Powell, CEO of Synteract. “Trials in this rapidly developing area come with their own unique set of challenges, particularly in components like recruitment and the high variability in global consensus on the standard of care. Our customers will greatly benefit from Lisa’s and Elisabeth’s strategic knowledge, delivery expertise, and long-standing relationships with sites and advocacy groups to address these needs. We are excited to welcome them to the team.”

Lisa Dilworth combines 18 years in study design, eligibility criteria, and overall program strategy with her prior work experience in clinical settings to bring a patient-focused mindset and strong relationships with advocacy groups to the team. She will provide leadership in rare and orphan diseases that span various therapeutic areas and specialties, including neurology, metabolic and endocrine, ophthalmology, oncology, hepatology, and others. Dilworth was previously director of therapeutic expertise, scientific affairs and rare disease at PRA Health Sciences and has held managerial roles at UCB and Chiltern International. She holds a bachelor’s degree in Integrative Biology from University of California, Berkeley and a master’s degree in Clinical Research from University of California, San Diego. She volunteers as a consultant, committee member, and speaker for the Myasthenia Gravis Foundation of America, Inc., and as consultant, advocate, and content contributor to Project Muscular Dystrophy.

Elisabeth Schrader has 20+ years of clinical research experience working in large, mid-size, and small CROs developing partnerships, delivery models, population and indication-specific operational delivery study strategies and training programs, and relationships with advocacy groups and global site networks. She will work closely with Synteract’s centers of development heads and customers in developing operational strategies for pediatric and rare disease programs as well as providing training and oversight to the project teams focused in these specialized areas of clinical focus. Schrader joins from Syneos where she was executive director, clinical development and a member of the Rare Disease Consortium and on the leadership team of the Pediatric Consortium. Prior to that she was senior customer operations director at IQVIA supporting customers with a rare disease and pediatric focus as well as leader in the Pediatric Center of Excellence. She holds a bachelor’s degree in Health Policy and Administration from University of North Carolina at Chapel Hill.

About Synteract

With 800 staff members across 21 countries, Synteract is an innovative, full-service contract research organization supporting biopharmaceutical companies in all phases of clinical development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries, working with more than 26,000 investigative sites and nearly 750,000 patients. It has contributed to more than 240 product approvals. The CRO offers a notable depth of expertise in oncology, dermatology, and neuro degenerative indications, as well as rare and orphan, pediatric, and immunotherapy studies. Connect on LinkedIn and Twitter.

Contact information

for Synteract
Hilary McCarthy, 508-829-2543
hilary@clearpointagency.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris23.10.2018 19:22Tiedote

Christo Georgiev, fintech entrepreneur and founder of myPOS, has confirmed his intention to open two new flagship stores in major European cities by the end of the year. The opening is part of an initiative to bring the product closer to potential customers, giving them a hands-on experience and a live demonstration of what myPOS has to offer. The two new stores will be opened in Barcelona, Spain and Paris, France – two of the most important markets for myPOS. “Our Spanish and French customers have always placed a tremendous amount of trust in us, and we in turn have worked hard to justify it,” Georgiev says. “Opening physical locations in Barcelona and Paris is an extension of that relationship. It’s important to test a product with your own hands before you choose to trust it, and if that’s true for TVs and phones why can’t it apply to POS terminals?” The Barcelona store will open as soon as November, followed shortly by the Paris one before the end of the year. myPOS has already ope

Christo Georgiev Announces the Arrival of myPOS AppMarket23.10.2018 19:11Tiedote

myPOS Europe Ltd., a leading card payments provider to small and medium-sized businesses in Europe, is introducing its own AppMarket – an innovative software platform for business applications that allows myPOS clients to find, download and use various apps for improved business performance. The development of myPOS AppMarket was driven by the necessity to meet the ever-changing business needs dictated by customer demand and behaviour. While the payment terminals myPOS offers come with a large number of innovative payments features, there are other business needs which remain uncaptured at the moment. myPOS founder Mr. Christo Georgiev says: “Individual businesses need a tailored approach when it comes to accepting payments for their services. Offering a fully customizable and complete omni-channel payments solution, which empowers businesses to stay agile, has always been in our foresight. Tapping into the familiarity of our everyday favourite device – the smartphone, pushed us even f

CNIM Presents a Rapid Version of The LCAT® Shore-to-Shore Featuring Unique Operational Capabilities23.10.2018 18:45Tiedote

The L-CAT® Shore-to-shore presented by CNIM at Euronaval 2018 delivers a major increase in performance for amphibious missions. The L-CAT® Shore-to-shore has been upgrated since its launch 2 years ago. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005869/en/ CNIM's amphibious craft, the L-CAT® Shore-to-shore (Photo: CNIM) The L-CAT® Shore-to-shore is now the only vessel with the ability to transport 80 tonnes at 25 knots in conditions up to sea state 5, land in shallow water (~1m) and accommodate 42 passengers for long distance trips. Highly maneuvrable, the L-CAT® Shore-to-shore provides exceptional operational flexibility for amphibious assaults and humanitarian operations, without compromising between speed and payload. Its wide loading platform (145 m²), ability to travel up to 800 nautical miles when loaded, self-defence and communication capabilities are tactical advantages for the projection of Forces. Its spee

Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia23.10.2018 16:03Tiedote

Exterior Plus, the out-of-home advertising platform of H.I.G. Capital, announces the acquisition of Impactmedia (the “Company”), a leading shopping mall advertising company, with over 630 million viewers in high-traffic premium locations throughout Spain. This is a major step forward in Exterior Plus’s consolidation strategy, as it aims to become the Spanish leader in out-of-home advertising with a unique, diversified and highly-competitive product portfolio, reaching very diverse audiences at a national level. Impactmedia is an experienced leader in shopping mall advertising, offering digital advertising as well as special marketing actions. The Company operates in over 90 shopping centers where it has more than 1,200 digital displays. The acquisition allows Exterior Plus to gain a strong presence near points of sale, a key value driver for advertisers. H.I.G. Capital acquired and established the Exterior Plus group in December 2015. The group currently markets more than 25,000 advert

Visa Brings a Simpler, Safer Experience to Digital Payments23.10.2018 16:00Tiedote

Visa (NYSE: V) today announced a continued commitment to reducing friction and improving security in digital commerce by reiterating support of the draft EMV® Secure Remote Commerce (SRC) Specification. The draft EMV SRC Specification provides a foundation for digital transactions that gives consumers, merchants and issuers a single digital point-of-sale, resulting in a consistent, convenient and secure way to pay. EMVCo has spent the last year gathering feedback from across the payment ecosystem on the specification. Visa now encourages merchants, issuers, acquirer gateways and other interested participants to provide feedback and comment during a 45-day public comment window. Once complete, EMVCo will publish the final specification. Shoppers are increasingly migrating to websites, mobile phones and voice-activated devices, but their buying experiences are full of friction because they are required to manually enter payment details. With SRC, consumers’ digital buying experiences wil

Active-Semi’s New PMICs Reduce Size and Increase Power Density with Leading Field Programable Technology23.10.2018 16:00Tiedote

The ACT88325 and ACT88326 PMICs are integrated field programmable ActivePMU™ power management units, also referred to as PMICs (Power Management ICs). The products are highly flexible with non-volatile memory and come pre-programmed and can be field programmed via I²C or via GPIOs for multiple applications. The ACT88325 powers up based on the preconfigured startup sequence as soon as power is applied to the input pin, whereas ACT88326 implements a Push Button Startup that relies on a customer’s interaction with, for example, a portable application like an Action Camera, Video Doorbell, Body Camera or other handheld applications. “Low external component count, extremely small WLCSP package and high configurability significantly speeds time to market and reduces PCB size and BOM cost,” says David Briggs, VP and General Manager of Power Solutions at Active-Semi. “The ACT88325 and ACT88326 are a great addition to our lineup and are specifically designed for the highest power density in SSD

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme